Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ESSA Pharma Inc. (EPIX)
|
Add to portfolio |
|
|
|
| Price: |
$13.88
| | Metrics |
| OS: |
44.1
|
M
| |
-18
|
% ROE
|
| Market cap: |
$612
|
M
| |
-33
|
% ROIC
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
($0.62)
| |
|
|
|
BVPS
|
$3.41
| |
4.07
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 0.9 | 0.1 | 0.6 | 0.0 | -0.2 | 0.0 | 0.0 | 5.0 |
| Revenue growth | 1075.8% | -86.4% | 2032.2% | -113.0% | | | -100.0% | |
| Cost of goods sold | 73.9 | 74.3 | 48.3 | 25.5 | 0.0 | 0.0 | 0.0 | 1.7 |
| Gross profit | -73.1 | -74.3 | -47.7 | -25.5 | -0.2 | 0.0 | 0.0 | 3.3 |
| Gross margin | -8169.4% | -97632.7% | -8525.1% | -97070.9% | 100.0% | | | 66.4% |
| Selling, general and administrative | | | | | 0.0 | 0.0 | 0.0 | 0.0 |
| Research and development | 24.4 | 24.3 | 12.1 | 6.7 | | | | |
| General and administrative | 12.5 | 12.9 | 11.4 | 5.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITA | -38.7 | -37.3 | -23.9 | -12.7 | 0.0 | 0.0 | 0.1 | 3.3 |
| EBITA margin | -4326.2% | -49076.8% | -4268.2% | -48416.9% | -17.1% | | | 66.4% |
| Amortization of intangibles | | | | | 0.0 | 0.0 | 0.1 | |
| EBIT | -38.7 | -37.3 | -23.9 | -12.7 | 0.0 | 0.0 | 0.0 | 3.3 |
| EBIT margin | -4326.2% | -49076.8% | -4268.2% | -48416.9% | 0.0% | | | 66.4% |
| Pre-tax income | -35.2 | -36.8 | -23.7 | -12.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income taxes | -0.1 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.3% | 0.1% | 1.2% | | | | | |
| Net income | -35.1 | -36.8 | -23.4 | -12.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net margin | -3925.5% | -48392.6% | -4188.8% | -48595.6% | 0.0% | | | 0.0% |
| |
| Diluted EPS | ($0.80) | ($0.96) | ($1.04) | ($1.51) | | | | |
| Shares outstanding (diluted) | 44.0 | 38.5 | 22.4 | 8.4 | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|